Flexibility in the administration schedule of varicella vaccination in healthy adolescents and young adults

Asian Pacific Journal of Allergy and Immunology

Volumn 20, Issue 4, 2002, Pages 241-245

  Kosuwon, Pensri ^a   Wasi, Chantapong ^b   Sutra, Sumitr ^b   Kositanont, Uraiwan ^a   Hutagalung, Yanee ^c   Bock, Hans L ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE; VARILIX;

ADOLESCENT; ADULT; ARTICLE; CHICKENPOX; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PAIN; PATIENT SELECTION; POPULATION RESEARCH; SEROCONVERSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THAILAND; TITRIMETRY; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS ATTENUATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; HUMANS; IMMUNIZATION SCHEDULE; VACCINES, ATTENUATED;

EID: 0038637903     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Guess HA, Broughton DD, Melton LJ, Kurland LT. Population based-studies of varicella complication. Pediatrics 1986; 78(suppl): 723-7.
2. Hammerschlag MR, Gershon A, Steinberg S, Gelb LD. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989; 160: 535-7.
3. Wallace MR, Bowler WZ, Murry NB, Brodine SK, Oldfield III EC. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 358-65.
4. Wallace MR, Bowler WA, Oldfield EC. Treatment of varicella in the immunocompetent adult. J Med Virol 1993; Suppl (1): 90-2.
5. Arbeter AM. Clinical trials of varicella vaccine in healthy adolescents and adults. Infect Dis Clin North Am 1996; 10(3): 609-15.
6. Preblud SR. Varicella: Complication and costs. Pediatrics 1986; 78 (suppl): 728-35.
7. Preblud SR, Orenstein WA, Bart KJ. Varicella: Clinical manifestation, epidemiology and healthy impact on children. Pediatr Inf Dis 1984; 3: 505-9.
8. Migasena S, Simasathien S, Desakorn V, et al. Seroprevalence of varicella-zoster virus antibody in Thailand. Int J Infect Dis 1997; 2(1): 26-30.
9. Meunch R, Nassim C, Niku S, et al. Seroepidemiology of varicella. J Infect Dis 1986; 153: 153-4.
10. Lolekha S, Tanthiprapa W, Sornchai P, et al. Effect of climatic factors and population density on varicella-zoster virus epidemiology within a tropical country. Am J of Trop Med Hyg 2001; 64(3): 131-6.
11. Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults. Vaccine 1995; 13(11): 967-72.
12. Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995; 95(5): 791-6.
13. White CJ, Kuter BJ, Hildelberg CS, et al. Varicella vaccine (Varivax) in healthy children and adolescents: Result from clinical trials, 1987 to 1989. Pediatrics 1991; 87(5): 604-10.
14. Rubio M, Tanaka J, Chitour K. SmithKline Beecham Biologicals' Oka varicella vaccine: Worldwide clinical experience. 3rd European Pediatric Congress, Madrid, Spain, 1998; 24-26 April.
15. Gershon AA, Steinberg S, NIAID Collaboration Varicella Vaccine Study Group. Live attenuated varicella vaccine: Protection in healthy adults in comparison to leukemic children. J Infect Dis 1990; 161: 661-6.